-
8m 37sPart 1 | Session 4 Late-Breaker Discussion: Findings from PACT-HF
-
2m 45sPart 2 | Session 1 Remote Patient Monitoring for Patients With Heart Failure: TELESAT
-
5m 3sPart 2 | Session 2 Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF
-
7m 19s
-
5m 24sPart 2 | Session 4 Timing of Cardio-Kidney Protection with SGLT2i
-
2m 54s
-
4m 40sPart 2 | Session 7 FINE-HEART: Design & Baseline Characteristics
-
11m 58sPart 2 | Session 8 HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
-
15m 26sPart 1 | Session 1 HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie
-
10m 15sPart 1 | Session 2 Late-Breaker Discussion: The TITRATE-HF Study
HFA 2024 — Late-breaker host, Dr Harriette Van Spall sat down with Dr Mikhail Kosiborod to discuss insights from the STEP-HFpEF programme.
STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the primary results of STEP-HFpEF, specifically in terms of the patients' NTproBNP levels. This study analysed both the effect of semaglutide on NTproBNP, as well as the effect of semaglutide on the primary and secondary endpoints of STEP-HFpEF according to patients' baseline NTproBNP.
Findings showed that all patients regardless of NTproBNP benefited from semaglutide as compared to placebo, both in terms of improvement in KCCQ Clinical Summary Score, and weight loss. However, patients at higher NTproBNP levels had greater improvement in KCCQ score than those with lower NTproBNP.
Recorded onsite at HFA 24, Lisbon.
Support: This is an independent discussion produced by Radcliffe Cardiology.
Editor: Mirjam Boros, Jordan Rance
Video Specialist: Tom Green, Oliver Miles
Interviewer: Jonathan McKenna
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.
Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.
For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an internationally known cardiologist, research methodologist, and senior scientist. She serves as an Associate Professor of Medicine at McMaster University, a Senior Scientist at the Population Health Research Institute, and Director of Implementation Science at the Baim Institute for Clinical Research in Boston.
Academic history
Dr Van Spall completed her BSc and MD at the University of Toronto, followed by residency and fellowship training in internal medicine and…
Mikhail Kosiborod
Professor of Medicine
Dr Mikhail Kosiborod is a cardiologist based in the United States, where he serves as Senior Vice President, Late-stage Development, CVRM at AstraZeneca and Professor of Medicine at the University of Missouri…
Comments